{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:04Z","timestamp":1792804144448,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1245\/s10434-019-08174-1","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:06:24Z","timestamp":1577991984000},"page":"2915-2926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma"],"prefix":"10.1245","volume":"27","author":[{"given":"Yun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Richard J.","family":"Straker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis A.","family":"Gimotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Amaravadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Schuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"issue":"6","key":"8174_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eight edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"8174_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452\u20132459. https:\/\/doi.org\/10.1200\/jco.2009.27.1627","journal-title":"J Clin Oncol"},{"key":"8174_CR3","unstructured":"Coit DG, Thompson JF, Albertini MR, et al. NCCN clinical practice guidelines in oncology: cutaneous melanoma (version 2.2019). April 2019. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed 15 Mar 2019."},{"issue":"19","key":"8174_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/nejmoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u20131855. https:\/\/doi.org\/10.1056\/nejmoa1611299","journal-title":"N Engl J Med."},{"issue":"19","key":"8174_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/nejmoa1709030","journal-title":"N Engl J Med."},{"issue":"19","key":"8174_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AM Eggermont","year":"2018","unstructured":"Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/nejmoa1802357","journal-title":"N Engl J Med."},{"issue":"11","key":"8174_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u20131654. https:\/\/doi.org\/10.1038\/s41591-018-0197-1","journal-title":"Nat Med"},{"issue":"11","key":"8174_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"C Blank","year":"2018","unstructured":"Blank C, Rozeman EA, Franchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u20131661. https:\/\/doi.org\/10.1038\/s41591-018-0198-0","journal-title":"Nat Med."},{"issue":"3","key":"8174_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454\u2013461. https:\/\/doi.org\/10.1038\/s41591-019-0357-y","journal-title":"Nat Med."},{"issue":"7","key":"8174_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u2013960. https:\/\/doi.org\/10.1016\/s1470-2045(19)30151-2","journal-title":"Lancet Oncol"},{"issue":"12","key":"8174_CR11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382\u20131399. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0577","journal-title":"Cancer Discov."},{"key":"8174_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. November 2017. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 1 Apr 2019."},{"issue":"8","key":"8174_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861\u20131868. https:\/\/doi.org\/10.1093\/annonc\/mdy226","journal-title":"Ann Oncol."},{"key":"8174_CR14","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019. Available at: https:\/\/www.R-project.org\/. Accessed 1 Jul 2019."},{"issue":"1","key":"8174_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/BF02967540","volume":"9","author":"T Ikeda","year":"2002","unstructured":"Ikeda T, Jinno H, Matsu A, Masamura S, Kitajima M. The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer. 2002;9(1):8\u201314.","journal-title":"Breast Cancer"},{"issue":"1","key":"8174_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339. https:\/\/doi.org\/10.1016\/s1470-2045(17)30777-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"8174_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19(2):181\u2013193. https:\/\/doi.org\/10.1016\/s1470-2045(18)30015-9","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"8174_CR18","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2019.37.15_suppl.9503","volume":"37","author":"AM Menzies","year":"2019","unstructured":"Menzies AM, Rozeman EA, Amaria RN, et al. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). J Clin Oncol. 2019;37(15 Suppl):9503. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.9503","journal-title":"J Clin Oncol"},{"issue":"14","key":"8174_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez RJ, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/nejmoa1709684","journal-title":"N Engl J Med."},{"issue":"10105","key":"8174_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u20131862. https:\/\/doi.org\/10.1016\/s0140-6736(17)31601-x","journal-title":"Lancet"},{"key":"8174_CR21","doi-asserted-by":"publisher","unstructured":"Weber JS, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann Oncol. 2019;30 Suppl\u00a05):v533-v563. https:\/\/doi.org\/10.1093\/annonc\/mdz255","DOI":"10.1093\/annonc\/mdz255"},{"issue":"12","key":"8174_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2159-8290.CD-16-1109","volume":"6","author":"I Melero","year":"2016","unstructured":"Melero I, Berraonda P, Rodriguez-Ruiz ME, Perez-Gracia JL. Making the most of cancer surgery with neoadjuvant immunotherapy. Cancer Discov. 2016;6(12):1312-1314. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1109","journal-title":"Cancer Discov"},{"key":"8174_CR23","first-page":"S7","volume":"26","author":"K Mahuron","year":"2019","unstructured":"Mahuron K, Levine L, Daud A, Alvarado M. Treatment outcomes of neoadjuvant immunotherapy in patients with locally advanced melanoma. Ann Surg Oncol. 2019;26:S7","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"8174_CR24","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20(7):e378\u2013e389. https:\/\/doi.org\/10.1016\/s1470-2045(19)30332-8","journal-title":"Lancet Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-08174-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:13:05Z","timestamp":1609459985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-08174-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["8174"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-08174-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Karakousis is the Principal Investigator in an investigator-initiated clinical trial of neoadjuvant pembrolizumab in patients diagnosed with clinical stage IIB\/C melanoma (NCT03757689), sponsored by Merck Sharp & Dohme Corp. Dr. Mitchell has had advisory roles with Merck, Bristol-Myers Squibb, Incyte, and Array BioPharma. Dr. Schuchter has participated in clinical trial activities with Bristol-Myers Squibb and Merck. Yun Song, Richard J. Straker III, Xiaowei Xu, David E. Elder, Phyllis A. Gimotty, Alexander C. Huang, and Ravi K. Amaravadi have declared no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}